Compare Infosys Limited (INFY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Zoetis Inc — how do they compare? Infosys Limited trades at $12.4 (market cap $50.55B), while Zoetis Inc trades at $73.8 (market cap $31.14B). The key difference: Infosys Limited is the larger of the two by market cap, and Infosys Limited pays the higher dividend (4.16%). Which is the better fit depends on your goals.
| INFY | ZTS | |
|---|---|---|
Market Cap | $50.55B | $31.14B |
Sector | Technology | Health |
52-Week High | $20.22 | $156.76 |
52-Week Low | $10.49 | $71.91 |
Enterprise Value | $48.30B | $38.70B |
Dividend Yield | 4.16% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.28, down 2.23% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported Q1 2027 revenue below expectations but maintained strong margins and AI growth, with a P/E of 15.56 and robust ROE of 32.12%. Recent news includes strategic AI collaborations and a CEO transition, while analyst sentiment remains cautious with a consensus price target of $11.05.
The outlook for INFY is balanced; solid profitability and AI adoption offer upside, but near-term revenue softness and elevated valuation pose risks. Investors should weigh strong cash flow and market position against competitive pressures and execution challenges in a volatile IT services market.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
